Microbiology Quiz: Metabolic Pathway Inhibitors

20 questions · exam conditions

0:00

Metabolic Pathway InhibitorsQuestion 1 of 20

Dapsone, an inhibitor of dihydropteroate synthase, is a key component of multidrug therapy for leprosy. A new experimental drug is found to be a potent inhibitor of the Mycobacterium leprae dihydrofolate reductase. What is the primary pharmacological rationale for proposing a combination therapy with dapsone and the new drug?

To achieve a synergistic bactericidal effect through sequential pathway blockade.

To reduce the risk of hemolysis, a known side effect of dapsone.

To ensure efficacy against both the tuberculoid and lepromatous forms of leprosy.

To target both actively replicating bacilli and dormant persister cells.

← Back to quizzes

Microbiology Quiz

Microbiology Quiz: Metabolic Pathway Inhibitors

Practice Metabolic Pathway Inhibitors in Microbiology with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.

What this quiz covers

This quiz focuses on Metabolic Pathway Inhibitors, giving you a quick way to practice the rules, question types, and explanations that matter most for Microbiology.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

All questions

Question 1

To achieve a synergistic bactericidal effect through sequential pathway blockade. (correct answer)
To reduce the risk of hemolysis, a known side effect of dapsone.
To ensure efficacy against both the tuberculoid and lepromatous forms of leprosy.
To target both actively replicating bacilli and dormant persister cells.

Explanation: When you encounter questions about antimicrobial combination therapy, focus on understanding how different drugs can work together to enhance treatment effectiveness. The key here is recognizing how sequential enzymatic pathway inhibition creates synergistic effects. Dapsone inhibits dihydropteroate synthase, which catalyzes an early step in bacterial folate synthesis. The experimental drug targets dihydrofolate reductase, which acts later in the same pathway to convert dihydrofolate to tetrahydrofolate. By blocking sequential steps in folate metabolism, these drugs prevent M. leprae from synthesizing essential nucleotides and amino acids needed for DNA replication and cell division. This sequential blockade creates a synergistic bactericidal effect that's more potent than either drug alone, making option A correct. Option B is wrong because reducing hemolysis isn't achieved through pathway synergy - this would require different mechanisms entirely. Option C incorrectly assumes the combination specifically targets different clinical forms of leprosy, when the mechanism described affects folate synthesis universally in M. leprae. Option D is incorrect because both drugs target the same metabolic pathway active primarily in replicating bacteria, not specifically dormant persister cells, which typically require different therapeutic approaches. Remember that synergistic drug combinations often work by targeting the same essential pathway at multiple points, creating a "double block" that's harder for bacteria to overcome through resistance mutations. Look for this pattern when evaluating antimicrobial combination therapies - sequential pathway inhibition is a powerful and commonly tested concept.

Question 2

The minimum inhibitory concentration (MIC) of sulfamethoxazole for a strain of E. coli is 32 µg/mL, and the MIC for trimethoprim is 2 µg/mL. In a checkerboard assay, bacterial growth is inhibited by a combination of 4 µg/mL of sulfamethoxazole and 0.25 µg/mL of trimethoprim. What pharmacological principle does this interaction demonstrate?

Synergism, as indicated by a fractional inhibitory concentration (FIC) index of 0.25. (correct answer)
Additivity, as the combined concentration is lower than the individual MICs.
Antagonism, because the two drugs compete for entry into the bacterial cell.
Indifference, because both drugs target the same overall metabolic outcome.

Explanation: The Fractional Inhibitory Concentration (FIC) index is calculated as (MIC of Drug A in combination / MIC of Drug A alone) + (MIC of Drug B in combination / MIC of Drug B alone). In this case, FIC = (4/32) + (0.25/2) = 0.125 + 0.125 = 0.25. An FIC index of ≤ 0.5 indicates synergism, meaning the combined effect of the drugs is significantly greater than the sum of their individual effects. Additivity would result in an FIC index of ~1.0, while antagonism would be > 1.0 (often > 4.0).

Question 3

A researcher performs minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) assays for sulfamethoxazole (SMX) and trimethoprim (TMP), both alone and in combination. Which set of results is most consistent with the known activity of these agents against a susceptible bacterium?

SMX: MIC=16, MBC=16; TMP: MIC=1, MBC=1; SMX+TMP: MIC=0.5, MBC=0.5
SMX: MIC=16, MBC>512; TMP: MIC=1, MBC>64; SMX+TMP: MIC=0.5, MBC=1 (correct answer)
SMX: MIC=16, MBC=64; TMP: MIC=1, MBC=128; SMX+TMP: MIC=20, MBC>512
SMX: MIC=16, MBC>512; TMP: MIC=1, MBC>64; SMX+TMP: MIC=0.5, MBC>32

Explanation: Sulfonamides and trimethoprim are typically bacteriostatic when used individually. This is reflected by an MBC that is much higher (often >32-fold) than the MIC. This indicates that the drug inhibits growth but does not kill the bacteria over a wide concentration range. However, when used in combination, the synergistic sequential blockade often results in bactericidal activity. This is reflected by an MBC that is very close to the MIC (typically an MBC/MIC ratio of ≤4). Option B correctly shows high MBC/MIC ratios for the individual drugs and a low MBC/MIC ratio (1/0.5 = 2) for the combination.

Question 4

A topical sulfonamide is found to be ineffective in treating a skin infection characterized by significant pus formation. In vitro tests confirm the bacterial isolate is highly susceptible to the same sulfonamide. What is the most likely reason for the treatment failure in vivo?

The low pH of the infected tissue hydrolyzes the sulfonamide into an inactive form.
The bacteria within the abscess have entered a dormant, non-dividing state.
The causative organism has rapidly developed a biofilm, preventing drug penetration.
Cellular debris in the pus provides high levels of PABA, which antagonizes the drug's action. (correct answer)

Explanation: This is a classic example of environmental antagonism. Pus and necrotic tissue contain breakdown products from lysed host and bacterial cells. Among these products is para-aminobenzoic acid (PABA), the natural substrate that sulfonamides compete with. The high local concentration of PABA in the abscess effectively neutralizes the sulfonamide by outcompeting it for the target enzyme, rendering the drug ineffective despite the bacterium's intrinsic susceptibility.

Question 5

The molecular structures of sulfonamide antibiotics are designed to act as competitive inhibitors by mimicking an essential bacterial metabolite. Which molecule's structure is most closely approximated by the sulfonamide core structure?

Dihydrofolic acid
Para-aminobenzoic acid (correct answer)
Tetrahydrofolic acid
Dihydropteroate pyrophosphate

Explanation: The efficacy of sulfonamides relies on their structural similarity to para-aminobenzoic acid (PABA). PABA is a key substrate for the enzyme dihydropteroate synthase. Because the sulfonamide molecule closely resembles PABA, it can fit into the enzyme's active site, but it cannot be used in the reaction. This competitive binding blocks the true substrate, PABA, from entering, thereby halting the folic acid synthesis pathway. The other options are other intermediates or products in the pathway but are not what sulfonamides mimic.

Question 6

A bacterial strain possesses a mutated folP gene, resulting in an altered dihydropteroate synthase that confers resistance to sulfamethoxazole. To which of the following antibiotics would this strain most likely exhibit cross-resistance?

Trimethoprim
Ciprofloxacin
Dapsone (correct answer)
Imipenem

Explanation: Cross-resistance occurs when a single resistance mechanism confers resistance to multiple drugs. In this case, resistance is due to modification of the target enzyme, dihydropteroate synthase. Therefore, the bacterium will likely be resistant to other drugs that target the same enzyme. Dapsone is a sulfone drug, structurally and mechanistically related to sulfonamides, which also inhibits dihydropteroate synthase. Trimethoprim (A), Ciprofloxacin (B), and Imipenem (D) all have different cellular targets (DHFR, DNA gyrase, and penicillin-binding proteins, respectively) and would not be affected by this specific resistance mechanism.

Question 7

A patient being treated with trimethoprim-sulfamethoxazole for a urinary tract infection experiences a relapse. The new bacterial isolate is found to be resistant to the combination therapy. Which genetic event is the most likely explanation for the acquisition of high-level resistance to both drugs simultaneously?

A single point mutation in the chromosomal gene for dihydropteroate synthase.
Acquisition of a transposon carrying genes for both a drug-resistant dihydropteroate synthase and a drug-resistant dihydrofolate reductase. (correct answer)
Selective upregulation of a multi-drug efflux pump that exports both trimethoprim and sulfamethoxazole.
A nonsense mutation in the gene encoding the PABA transport protein, preventing substrate uptake.

Explanation: High-level resistance to the synergistic combination of trimethoprim and sulfamethoxazole typically requires the bacterium to overcome the inhibition of both target enzymes. Acquiring a mobile genetic element, such as a transposon or plasmid, that carries resistant versions of both dihydropteroate synthase (folP) and dihydrofolate reductase (folA) is a common and efficient mechanism for gaining resistance to both drugs at once. A mutation in only one target (A) would not explain resistance to the other drug. While an efflux pump (C) could confer resistance, pumps with dual specificity for these structurally dissimilar drugs are not the primary mechanism. Preventing PABA uptake (D) would be detrimental to the bacterium as it would be unable to synthesize folate, and is not a known resistance mechanism.

Question 8

Some bacterial species, like Enterococcus faecalis, exhibit intrinsic resistance to trimethoprim-sulfamethoxazole. The mechanism in many strains involves a gene that encodes a high-affinity folate uptake transporter. How does this system confer resistance?

It allows the bacterium to import PABA from the environment to outcompete the sulfamethoxazole.
It functions as a promiscuous efflux pump, actively removing both antimicrobial agents from the cell.
It allows the bacterium to utilize pre-formed folate from the host, bypassing the need for the inhibited synthesis pathway. (correct answer)
It modifies the imported folate into a form that can be used by the drug-inhibited enzymes.

Explanation: The basis of sulfonamide and trimethoprim efficacy is that bacteria must synthesize folate de novo, while their hosts (humans) obtain it from their diet. Therefore, bacteria that can acquire an alternative pathway, such as importing pre-formed folate from the host environment via a transporter, can survive even when their internal synthesis pathway is blocked. This bypass mechanism renders the metabolic pathway inhibitors ineffective.

Question 9

A strain of Staphylococcus aureus develops resistance to sulfamethoxazole. Analysis reveals its dihydropteroate synthase enzyme is unchanged, but the intracellular concentration of para-aminobenzoic acid (PABA) is 50 times higher than in the susceptible parent strain. What is the mechanism of resistance?

The excess PABA binds to and sequesters the sulfamethoxazole, preventing it from reaching its target enzyme.
The bacterium has acquired a novel dihydropteroate synthase that uses a substrate other than PABA.
The high concentration of the natural substrate, PABA, outcompetes the sulfonamide for the enzyme's active site. (correct answer)
The excess PABA acts as an allosteric activator of the enzyme, increasing its Vmax and overcoming inhibition.

Explanation: Sulfonamides are competitive inhibitors that act by mimicking PABA and binding to the active site of dihydropteroate synthase. According to the principles of competitive inhibition, the effect of the inhibitor can be overcome by increasing the concentration of the natural substrate. By overproducing PABA, the bacterium ensures that the enzyme is more likely to bind to PABA than to the sulfonamide, thus allowing folic acid synthesis to proceed, leading to resistance.

Question 10

A bacteriostatic concentration of a sulfonamide drug is added to a culture of susceptible bacteria. As a direct result of inhibiting dihydropteroate synthase, which downstream process will be the first to be significantly impaired?

The formation of the 30S ribosomal initiation complex.
The synthesis of thymidylate and purine nucleotides. (correct answer)
The transpeptidation reaction in peptidoglycan synthesis.
The generation of a proton motive force via the electron transport chain.

Explanation: Sulfonamides inhibit the synthesis of folic acid. The active form, tetrahydrofolate (THF), is a crucial coenzyme that donates one-carbon units for the synthesis of essential metabolites. Among the most critical of these are thymidylate (the 'T' in DNA) and purines (the 'A' and 'G' in DNA and RNA). Inhibition of the folate pathway leads directly to a shortage of THF, which in turn halts the production of these necessary DNA precursors, thereby arresting DNA replication and cell division. The other processes are inhibited by different classes of antibiotics (A: aminoglycosides/tetracyclines, C: beta-lactams, D: drugs like daptomycin).

Question 11

The low pH of the infected tissue hydrolyzes the sulfonamide into an inactive form.
The bacteria within the abscess have entered a dormant, non-dividing state.
The causative organism has rapidly developed a biofilm, preventing drug penetration.
Cellular debris in the pus provides high levels of PABA, which antagonizes the drug's action. (correct answer)

Question 12

A single point mutation in the chromosomal gene for dihydropteroate synthase.
Acquisition of a transposon carrying genes for both a drug-resistant dihydropteroate synthase and a drug-resistant dihydrofolate reductase. (correct answer)
Selective upregulation of a multi-drug efflux pump that exports both trimethoprim and sulfamethoxazole.
A nonsense mutation in the gene encoding the PABA transport protein, preventing substrate uptake.

Question 13

Synergism, as indicated by a fractional inhibitory concentration (FIC) index of 0.25. (correct answer)
Additivity, as the combined concentration is lower than the individual MICs.
Antagonism, because the two drugs compete for entry into the bacterial cell.
Indifference, because both drugs target the same overall metabolic outcome.

Question 14

Dihydrofolic acid
Para-aminobenzoic acid (correct answer)
Tetrahydrofolic acid
Dihydropteroate pyrophosphate

Question 15

SMX: MIC=16, MBC=16; TMP: MIC=1, MBC=1; SMX+TMP: MIC=0.5, MBC=0.5
SMX: MIC=16, MBC>512; TMP: MIC=1, MBC>64; SMX+TMP: MIC=0.5, MBC=1 (correct answer)
SMX: MIC=16, MBC=64; TMP: MIC=1, MBC=128; SMX+TMP: MIC=20, MBC>512
SMX: MIC=16, MBC>512; TMP: MIC=1, MBC>64; SMX+TMP: MIC=0.5, MBC>32

Question 16

The growth of a susceptible bacterium is completely halted by trimethoprim in a defined minimal medium. Which of the following supplements added to the medium is most likely to restore bacterial growth?

An excess of para-aminobenzoic acid (PABA).
An excess of dihydrofolic acid (DHF).
A mixture of thymidine, purines, and methionine. (correct answer)
Glutamic acid and pteridine precursors.

Explanation: Trimethoprim inhibits dihydrofolate reductase, preventing the formation of tetrahydrofolate (THF). THF is essential for donating one-carbon units to synthesize key metabolites. Instead of supplying THF itself (which is often unstable or not transported), growth can be rescued by providing the downstream products that can no longer be synthesized. These include thymidine, purines (adenine, guanine), and certain amino acids like methionine. Providing substrates from earlier in the pathway (A, D) or the direct substrate of the blocked enzyme (B) would be ineffective.

Question 17

Trimethoprim
Ciprofloxacin
Dapsone (correct answer)
Imipenem

Question 18

Isoniazid (inhibits mycolic acid synthesis) and sulfonamides (inhibit folate synthesis) are both inhibitors of essential metabolic pathways. What is the most fundamental difference between their principles of selective toxicity?

Isoniazid targets a pathway for cell envelope synthesis, while sulfonamides target nucleotide synthesis.
Isoniazid is a prodrug requiring activation, whereas sulfonamides are active upon administration.
Isoniazid's target pathway is entirely absent in humans, while sulfonamides' target pathway is present in bacteria but bypassed in humans. (correct answer)
Isoniazid acts bactericidally against dividing cells, while sulfonamides are purely bacteriostatic.

Explanation: The concept of selective toxicity relies on exploiting differences between the pathogen and the host. The most fundamental difference is the presence or absence of the drug's target pathway. Mycolic acid synthesis is a pathway unique to Mycobacterium and a few related genera; it is completely absent in eukaryotes. In contrast, many bacteria rely on the folate synthesis pathway, but humans do not have this pathway because they obtain folate from their diet (a bypass). While the other statements are largely true (A, B, D), they describe properties of the drugs or the general function of the pathways, not the core reason for their selective toxicity.

Question 19

A bacterium acquires a mutation in its chromosomal folP gene (dihydropteroate synthase) that confers sulfamethoxazole resistance. Subsequently, it acquires a mutation in its chromosomal folA gene (dihydrofolate reductase) conferring trimethoprim resistance. The double mutant is now resistant to both drugs but grows very slowly and displays a new requirement for thymidine in the growth medium. What does this acquired auxotrophy most likely suggest?

The mutations conferring drug resistance also severely impaired the normal catalytic efficiency of the respective enzymes. (correct answer)
The antibiotics induced off-target mutations in the thymidylate synthase gene.
The bacterium has evolved a new pathway where thymidine directly inhibits the mutated enzymes.
The resistant enzymes now produce a toxic metabolic byproduct that is neutralized by exogenous thymidine.

Explanation: When you encounter questions about antibiotic resistance mutations coupled with growth defects, think about the trade-offs bacteria face between survival and fitness. This question tests your understanding of how resistance mutations can compromise normal enzyme function. The key insight here is understanding the folate synthesis pathway. Both folP (dihydropteroate synthase) and folA (dihydrofolate reductase) encode enzymes essential for folate metabolism, which ultimately produces thymidine nucleotides for DNA synthesis. When this bacterium acquired mutations to resist sulfamethoxazole and trimethoprim, it gained survival advantages against these drugs but developed slow growth and thymidine auxotrophy. This pattern strongly suggests that answer A is correct: the resistance mutations impaired the normal catalytic efficiency of both enzymes. The mutations likely altered active sites enough to prevent drug binding while simultaneously reducing the enzymes' ability to process their natural substrates efficiently. This creates a metabolic bottleneck in thymidine production, explaining why external thymidine supplementation rescues growth. Answer B is incorrect because the auxotrophy appears linked to the resistance mutations themselves, not off-target effects on thymidylate synthase. Answer C misunderstands the relationship—thymidine isn't inhibiting the enzymes but rather compensating for their reduced function. Answer D incorrectly suggests thymidine neutralizes toxins, when it's actually supplementing deficient metabolic output. Remember: resistance mutations often come with fitness costs. When you see drug resistance paired with growth defects or nutritional requirements, consider whether the resistance mechanism has compromised normal cellular processes.

Question 20

A microbiologist prepares four liquid cultures of a bacterium in a minimal medium to investigate its susceptibility to a sulfonamide drug.

Culture 1: Minimal medium only.
Culture 2: Minimal medium + sulfonamide.
Culture 3: Minimal medium + sulfonamide + para-aminobenzoic acid (PABA).
Culture 4: Minimal medium + sulfonamide + folic acid.

After incubation, growth is observed in Cultures 1 and 3, but not in Cultures 2 and 4.

Based on these results, what can be concluded about the bacterium's physiology and interaction with the sulfonamide?

The sulfonamide's inhibitory effect is irreversible and bactericidal.
The bacterium requires an external source of PABA for folic acid synthesis.
The bacterium synthesizes its own folic acid and lacks an efficient uptake system for exogenous folate. (correct answer)
The bacterium possesses an efflux pump that is specifically activated by PABA to export the sulfonamide.

Explanation: Growth in Culture 1 shows the bacterium can grow in minimal medium, meaning it synthesizes all essential components, including folic acid. Lack of growth in Culture 2 shows the sulfonamide inhibits this synthesis. Growth in Culture 3 demonstrates that excess PABA can outcompete the sulfonamide (a competitive inhibitor), rescuing growth. The lack of growth in Culture 4 is critical; it shows that even when the final product (folic acid) is provided, the bacterium cannot use it, indicating it lacks a transporter to import it. This is a key aspect of the selective toxicity of folate synthesis inhibitors.